- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.16 Å
- Oligo State
- homo-tetramer
- Ligands
- 4 x OXL: OXALATE ION(Non-covalent)
- 4 x FBP: 1,6-di-O-phosphono-beta-D-fructofuranose(Non-covalent)
FBP.2: 19 residues within 4Å:- Chain A: L.347, T.348, T.349, T.350, R.352, S.353, W.398, V.402, R.405, T.429, G.430, W.431, R.432, P.433, G.434, S.435, G.436, Y.437, T.438
17 PLIP interactions:17 interactions with chain A- Hydrogen bonds: A:T.348, A:T.349, A:T.349, A:T.350, A:G.351, A:R.352, A:S.353, A:S.353, A:G.430, A:G.430, A:G.434, A:S.435, A:G.436, A:Y.437
- Water bridges: A:R.405, A:T.438
- Salt bridges: A:R.405
FBP.5: 18 residues within 4Å:- Chain B: L.347, T.348, T.349, T.350, G.351, R.352, S.353, W.398, R.405, T.429, G.430, R.432, P.433, G.434, S.435, G.436, Y.437, T.438
16 PLIP interactions:16 interactions with chain B- Hydrogen bonds: B:L.347, B:L.347, B:T.348, B:T.348, B:T.349, B:T.349, B:T.350, B:G.351, B:S.353, B:S.353, B:G.434, B:G.434, B:G.436, B:Y.437
- Water bridges: B:R.405
- Salt bridges: B:R.405
FBP.8: 17 residues within 4Å:- Chain C: L.347, T.348, T.349, T.350, R.352, S.353, W.398, R.405, T.429, G.430, R.432, P.433, G.434, S.435, G.436, Y.437, T.438
14 PLIP interactions:14 interactions with chain C- Hydrogen bonds: C:T.349, C:T.349, C:T.350, C:S.353, C:S.353, C:G.430, C:G.434, C:G.434, C:G.434, C:G.436, C:Y.437
- Water bridges: C:R.405, C:R.405
- Salt bridges: C:R.405
FBP.13: 17 residues within 4Å:- Chain D: L.347, T.348, T.349, T.350, R.352, S.353, W.398, R.405, T.429, G.430, R.432, P.433, G.434, S.435, G.436, Y.437, T.438
15 PLIP interactions:15 interactions with chain D- Hydrogen bonds: D:L.347, D:T.348, D:T.349, D:T.349, D:T.350, D:G.351, D:R.352, D:S.353, D:R.405, D:G.430, D:G.434, D:G.434, D:G.436, D:Y.437
- Salt bridges: D:R.405
- 2 x MG: MAGNESIUM ION(Non-covalent)
- 2 x 01: 4-[4-[[7-(azetidin-1-yl)-2,1,3-benzoxadiazol-4-yl]sulfonyl]piperazin-1-yl]sulfonylbenzene-1,2-diol
01.7: 21 residues within 4Å:- Chain A: F.40, L.41, L.44, L.269, D.270, Y.306, Q.309, L.310, E.313
- Chain C: F.40, L.41, L.44, G.231, N.234, L.269, D.270, G.271, Y.306, Q.309, L.310, E.313
11 PLIP interactions:7 interactions with chain A, 4 interactions with chain C- Hydrophobic interactions: A:L.41, A:L.44, A:Q.309, A:L.310, C:N.234
- Hydrogen bonds: A:D.270, C:E.313
- pi-Stacking: A:F.40, C:F.40
- pi-Cation interactions: A:F.40, C:F.40
01.11: 21 residues within 4Å:- Chain B: F.40, L.41, L.44, N.234, L.269, D.270, Y.306, Q.309, L.310, E.313
- Chain D: F.40, L.41, L.44, G.231, N.234, L.269, D.270, Y.306, Q.309, L.310, E.313
9 PLIP interactions:4 interactions with chain D, 5 interactions with chain B- Hydrophobic interactions: D:Q.309, D:L.310, B:L.41, B:L.44
- pi-Stacking: D:F.40, B:F.40, B:F.40
- pi-Cation interactions: D:F.40, B:F.40
- 1 x K: POTASSIUM ION(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Nilsson, O. et al., Fluorescent binding assay for allosteric ligands of liver pyruvate kinase. Eur.J.Med.Chem. (2025)
- Release Date
- 2025-08-13
- Peptides
- Isoform L-type of Pyruvate kinase PKLR: ABCD
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
BB
DC
FD
H
SMTL ID : 9r3l.2 (1 other biounit)
Structure of liver pyruvate kinase in complex with fluorescent probe 4d
Isoform L-type of Pyruvate kinase PKLR
Related Entries With Identical Sequence
5sc8.1 | 5sc8.2 | 5sc9.1 | 5sc9.2 | 5sca.1 | 5sca.2 | 5scb.1 | 5scb.2 | 5scc.1 | 5scc.2 | 5scd.1 | 5scd.2 | 5sce.1 | 5sce.2 | 5scf.1 | 5scf.2 | 5scg.1 | 5scg.2 | 5sch.1 | 5sch.2 | 5sci.1 | 5sci.2 | 5scj.1 | 5scj.2 | 5sck.1 | 5sck.2 | 5scl.1 | 5scl.2 | 5sdt.1 | 5sdt.2 more...less...7frv.1 | 7frv.2 | 7frw.1 | 7frw.2 | 7frx.1 | 7frx.2 | 7fry.1 | 7fry.2 | 7frz.1 | 7frz.2 | 7fs0.1 | 7fs0.2 | 7fs1.1 | 7fs1.2 | 7fs2.1 | 7fs2.2 | 7fs3.1 | 7fs3.2 | 7fs4.1 | 7fs4.2 | 7fs5.1 | 7fs5.2 | 7fs6.1 | 7fs6.2 | 7fs7.1 | 7fs7.2 | 7fs8.1 | 7fs8.2 | 7fs9.1 | 7fs9.2 | 7fsa.1 | 7fsa.2 | 7fsb.1 | 7fsb.2 | 7fsc.1 | 7fsc.2 | 7fsd.1 | 7fsd.2 | 7qdn.1 | 7qdn.2 | 7qzu.1 | 7qzu.2 | 9r3h.1 | 9r3h.2 | 9r3i.1 | 9r3l.1 | 9r3m.1 | 9r3m.2 | 9r3o.1 | 9r3o.2